Artiva aims for $116M in second attempt at IPO to boost NK cell therapy pipeline

Kyle LaHucik

Senior Reporter

Clinical-stage cell therapy developer Artiva Biotherapeutics will seek about $116 million in net proceeds from its proposed initial public offering, according to an updated SEC …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Artiva aims for $116M in second attempt at IPO to boost NK cell therapy pipeline

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Exclusive: Influential Democrat will oppose Biosecure Act ahead of House vote

Astellas CEO talks future beyond Xtandi as Japanese drugmaker puts roots in Boston

BridgeBio sticks to script for ATTR-CM as Alnylam cleans up ‘typo’ snafu

Roche's Spark loses CEO to RNA upstart; Ex-Elevation Oncology chief takes over at Affimed

Lilly inks obesity deal with seed-stage RNA startup as its genetic medicines effort enters the spotlight

How to secure full enrollment and a 30x ROI: A conversation with the CEO of the boutique enrollment agency doing just ...

Arti­va aims for $116M in sec­ond at­tempt at IPO to boost NK cell ther­a­py pipeline

Senior Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Artiva aims for $116M in second attempt at IPO to boost NK cell therapy pipeline